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Background: Aptamers have been widely used as targeted therapeutic agents due to its
relatively small physical size, flexible structure, high specificity, and selectivity. Aptamers
functionalized nanomaterials, not only enhance the targeting of nanomaterials, but can also
improve the stability of the aptamers. We developed aptamer C2NP (Apt) conjugated straight
DNA nanotubes (S-DNT-Apt) and twisted DNA nanotubes (T-DNT-Apt) as nanocarriers for
doxorubicin (DOX).
Methods: The twisted DNA nanotubes (T-DNT) and straight DNA nanotubes (S-DNT)
were assembled with a scaffold and hundreds of staples. Apt was site-specifically anchored
on DNA nanotubes with either different spatial distribution (3 or 6 nm) or varied stoichio-
metry (15Apt or 30Apt). The developed nanocarriers were characterized with agarose gel
electrophoresis and transmission electron microscopy. The drug loading and release in vitro
were evaluated by measuring the fluorescence intensity of DOX using a microplate reader.
The stability of DNT in cell culture medium plus 10% of FBS was evaluated by agarose gel
electrophoresis. The cytotoxicity of DNA nanostructures against K299 cells was tested with
a standard CCK8 method. Cellular uptake, cell apoptosis, cell cycle and reactive oxygen
species level were investigated by flow cytometry. The expression of p53 was examined by
Western Blot.
Results: T-DNT-30Apt-6 exhibited the highest cytotoxicity when the concentration of Apt
was 120 nM. After intercalation of DOX, the cytotoxicity of DOX@T-DNT-30Apt-6 was
further enhanced due to the combination of chemotherapy of DOX and biotherapy of Apt.
The enhanced cytotoxicity of DOX@T-DNT-30Apt-6 can be explained by the increase in the
cellular uptake, cell apoptosis and intracellular ROS levels. Additionally, the interaction
between Apt and its receptor CD30 could upregulate the expression of p53.
Conclusion: These results demonstrate that both stoichiometry and spatial arrangement of
Apt on T-DNT-Apt influence the anticancer activity. The developed twisted DNA nanotubes
may be a solution for the synergistic treatment of cancer.
Keywords: DNA nanotubes, aptamers, controlled spatial distribution, biotherapy and
chemotherapy
Introduction
Nanocarriers have been widely used for cancer therapy.1 These nanocarriers include
inorganic materials2 and organic materials.3 Recently, an emerging natural material,
DNA, has drawn much attention for drug delivery. Based on the complementary base
pairing rule, hundreds of short single-stranded DNA (ssDNA, staples) can hybridize to
a long single-stranded DNA (scaffold) and be folded into a two-dimension (2D) or
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three-dimension (3D) DNA origami nanostructure.4
Doxorubicin (DOX) has been widely used for cancer
therapy.5–7 It can noncovalently bind duplex DNA by the
interaction between the amino group of DOX and the cyto-
sine of DNA.8 DOX-loaded DNA nanostructures have been
used for cancer therapy.9 However, DOX delivered by these
nanocarriers can only passively accumulate at the tumor site.
DNA aptamers are short oligonucleotides which can
specifically bind to their receptors with high affinity. DNA
aptamers immobilized nanocarriers, such as mesoporous
silica nanoparticles,10 gold nanoparticles,11 protein
nanoparticles,12 polymer nanoparticles,13 etc., enhanced
not only the targeting specificity of the nanocarriers but
also improved the stability of aptamers. Given these
advantages, DNA aptamers modification has been an
excellent solution to enhance the targeting specificity of
nanocarriers.14 DNA aptamers can be immobilized on
DNA nanostructures either by extending staples with the
sequence of aptamers15 or by hybridization method.16
DNA aptamer C2NP (Apt) is a 31 nt oligonucleotide
with high affinity and specificity to CD30 receptor which
is a diagnostic biomarker and overexpressed in tumor
cells, such as K299 cells (human anaplastic large cell
lymphoma cell line). It was reported that Apt interacts
with its receptor and induces cell apoptosis.17 Apt probe
had been developed and exhibited high sensitivity and
a long-lasting signal in vivo.18 Our previous work also
showed that Apt modified rectangular DNA origami
nanostructures (RE-4Apt and RE-16Apt) increased the
targeting delivery and nanocarriers with a high density of
Apt (RE-16Apt) exhibited stronger anti-cancer activity
in vitro.19
Extracellular matrix (ECM) plays a vital role in cell
adhesion, spreading, and migration. It was reported that
the distance and amount of ECM-protein affected cell
binding and spreading. ECM-protein micropatterned sub-
strate can guide the shape of cells.20 Besides the ECM-
protein, ligands can also influence cell behavior.
Nanoscale arrangements of ephrin-A5 can affect EphA2
receptor activation in human breast cancer cells.21 Inspired
by these findings, we would like to find out how Apt with
different spatial distribution and stoichiometry impacts the
cell activities.
To this end, we used twisted DNA nanotubes (T-DNT)
as carriers of Apt. We modified the T-DNT with either 15
or 30 of Apt which were defined as DOX@T-DNT-15Apt
and DOX@T-DNT-30Apt. Given that the linear distance
between the binding sites of CD30 is 5.7 nm,22 we
designed Apt modified nanotubes with the spatial distance
of 3 or 6 nm which were donated as DOX@T-DNT-15Apt-
3, DOX@T-DNT-30Apt-3, DOX@T-DNT-15Apt-6,
DOX@T-DNT-30Apt-6 respectively. The spatial distribu-
tion of Apt was firstly designed on straight DNT (S-DNT)
map, and Apt was then modified at the same positions on
T-DNT. The design and the illustration of each DNT can
be found in Figure S2. We firstly compared the biotherapy
of Apt modified S-DNT (S-DNT-30Apt-3, S-DNT-30Apt-
6) and T-DNT (T-DNT-30Apt-3, T-DNT-30Apt-6) to con-
firm that the spatial distribution of Apt on T-DNT
remained the same as designed in S-DNT. An anti-cancer
drug, doxorubicin (DOX), was then loaded to the DNA
nanotubes for the chemotherapy. In our present study, the
effects of spatial distribution and stoichiometry of Apt on
cell behaviors were investigated. Both bioactivities of Apt
and chemotherapy of DOX were studied. Furthermore, the
anti-tumor mechanism of Apt anchored T-DNT was
explored. We demonstrated that Apt anchored T-DNT
with different spatial distribution and stoichiometry
showed various anti-cancer activities. DOX@T-DNT-
30Apt-6 increased the biotherapy of Apt and chemother-
apy of DOX. Western blot results showed that Apt induces
cell apoptosis by upregulation of p53 expression in K299
cells. Our results indicate that Apt modified T-DNT is not
only a promising strategy for targeting delivery but also an
efficient solution for the synergistic treatment of cancer.
Materials and Methods
Materials
Scaffolds (7560 and 8634) were derived from M13mp18
which was donated by Prof. Dr. B. Högberg (Karolinska
Institutet, Sweden). C2NP and single-stranded DNA was
synthesized by Bioneer (Daejeon, Korea). K299 cells
(human anaplastic large cell lymphoma cell line) were
obtained from CoBioer (Nanjing, China). Agarose was
supplied by Biowest (Nuaill´e, France). Fetal bovine
serum (FBS) was purchased from BI (Kibbutz, Israel).
Cell apoptosis assay kit, cell cycle kit, DCFH-DA cellular
reactive oxygen species assay kit, and DOX hydrochloride
(DOX∙HCl) were obtained from Solarbio (Beijing, China).
Dihydrochloride (DAPI), ethidium bromide (EB), 1Kbp
DNA Marker, DNA loading buffer, 4% paraformaldehyde,
phosphate-buffered solution (PBS) powder, and Difco
Skim Milk were supplied by Solarbio (Beijing, China).
The following antibodies were used: anti-p53 (catalog
number: WL01333; Wanleibio). Rabbit monoclonal anti-β-
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actin (1:1000, catalog number WL01774; Wanleibio,
China) was used as a housekeeping protein. All other
chemicals were obtained from Aladdin (Shanghai,
China). All commercial chemicals and agents were used
without any purification and modification.
Preparation of DNT
Twisted and straight DNT (T-DNT and S-DNT) were
assembled following Rothmund’s method.23 Briefly,
scaffold (100 nM, 2 µL) and staples (200 nM, 5 µL)
were mixed in TEM buffer (Tris 5 mM, EDTA 1 mM,
MgCl2 5 mM, pH 7.8) with a final volume of 40 µL.
Folding was carried out by rapid heating from 25 to 80°
C (4°C/s, maintained at 80°C for 5 min), followed by
slow cooling from 80 to 60°C (0.004°C/s, maintained at
60°C for 10 min) and from 60 to 24°C (0.001°C/s). For
the second slow cooling step, the temperature was main-
tained for 400 s after every one-degree drop. Aptamer
C2NP anchored DNT (T-DNT-15Apt-3, T-DNT-15Apt-6,
T-DNT-30Apt-3, T-DNT-30Apt-6, S-DNT-30Apt-3,
S-DNT-30Apt-6) were constructed by the same proce-
dure with prolonged staples. Microscope visible carriers,
FAM-T-DNT-30Apt-6, were prepared by FAM-labeled
staples. The obtained DNT was stored at 4°C for further
study.
Characterization of DNT
DNT were characterized by agarose gel electrophoresis
and transmission electron microscopy (TEM). For the
agarose gel electrophoresis, 1.3 μL of EB (10 μg/mL)
was added for gel imaging. Samples mixed with 6×loading
buffer (1:0.2, v/v) were loaded to the pockets of agarose
gel (1.5%, in 1×TBE buffer) which was later run at 70 V in
an ice bath. After 4 h, the gel was imaged by a gel imaging
system (Biorad, USA). The morphology of DNT was
further imaged with TEM (FEI, America). DNT (2 μL,
4 nM) was spotted on a glow-discharged, carbon-coated
Formvar grid, and incubated for 20 s, followed by staining
with uranyl formate (2%, w/v, in water). The excess solu-
tion was removed by filter paper, followed by observation
with TEM.
DOX Loading and Release
A calibration curve of DOX, ranging from 4 to 256 µM,
was firstly built by a microplate reader for the quantifica-
tion of DOX (BioTek, USA; λex=485 nm, λem=591 nm).
DOX@T-DNT-30Apt was obtained by incubating
DOX∙HCl solution and T-DNT-30Apt-6 at room tempera-
ture in the dark. The concentration of DOX was optimized
to get the maximum loading capacity. Firstly, various
amounts of DOX (20 μL; 16, 32, 64, 128, 256, 512, and
1024 μM) were incubated with T-DNT-30Apt-6 (20 μL, 4
nM). After 3 h, DOX@T-DNT-30Apt-6 was centrifuged
down (15,000 rpm, 10 min) and the fluorescence (F) of
free DOX in the supernatant was measured by the micro-
plate reader and the concentration (C) was calculated by
the calibration curve. The drug-loading capacity of
DOX@T-DNT-30Apt-6 was determined by equation (1):
Loading
capacity %ð Þ ¼
CDOXadded  V CDOXsupernatant  V
CDOXadded  V
 100% (1)
The UV-vis spectra of the resulting nanocarriers were
recorded by a UV-vis spectrophotometer (Agilent,
USA) to confirm the successful encapsulation of
DOX. The zeta potential of the nanocarriers was mea-
sured by zeta potential analyzer using a Zetasier
Nano-ZS (Malvern, UK).
Release property of DOX was studied by a dialysis
method.15 Typically, DOX solution, DOX@S-DNT-
30Apt-6 or DOX@T-DNT-30Apt-6 (4 nM, 20 μL) was
enclosed in Slide-A-Lyzer™ MINI Dialysis Devices
(Thermo Fisher, Germany) which were floated in PBS
(pH7.4, 37°C). At the set time points (0.5, 1, 2, 4, 8, 12,
24, and 48 h), three dialysis tubes of each sample were
taken out and the concentration of DOX remained inside
the tube was quantified. The cumulative release was cal-
culated by equation (2):
Cumulative
release %ð Þ ¼
CDOX in total  V CDOX remaining  V
CDOX in total  V
 100% (2)
Stability Evaluation
The stability of both DOX and T-DNT were investigated
by monitoring the fluorescence intensity of DOX and
migration of T-DNT in agarose gel, respectively. To this
end, free DOX (64 μM) and DOX@T-DNT-30Apt-6 (4
nM) were incubated with cell culture medium with 10% of
FBS in the dark at 37°C. Samples (5 μL) were collected at
set time points (0, 2, 4, 6, 8, 12, 24 and 48 h). The
fluorescence intensity (F) of DOX was determined by
a microplate reader. Typically, samples were mixed with
DMSO (2 μL) and PBS (43 μL, pH7.4). The mixtures
were shaken at 100 rpm for 3 min before measurement.
Dovepress Chen et al
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The relative stability of DOX was calculated via equa-
tion (3):
Relative stability %ð Þ ¼ Fsample
Foriginal
 100% (3)
The migration of T-DNT was analyzed by agarose gel
electrophoresis as the same procedure for the characteriza-
tion of T-DNT.
Cell Culture
K299 cells were cultivated in RPMI 1640 with 10% of
FBS under standard conditions (CO2: 5%, temperature:
37°C, humidity: 100%). Cells were split every two or
three days. Only cells in the exponential phase were used
for the following experiments.
In vitro Anticancer Activity
Anticancer activity of the developed nanocarriers was tested
against K299 cell line by a standard cell counting-8 kit
(CCK8) assay.15 K229 cells were seeded in 96 well plates
at a density of 1×104 cells/well and incubated under standard
cell culture conditions for 12 h before each experiment.
Firstly, various concentrations of T-DNT (1, 2, 3, 4 and 5
nM) and MgCl2 (0.625, 1.25, 2.5 and 6.25 mM) were treated
with K299 cells for 48 h to test the cytotoxicity of T-DNTand
MgCl2. Secondly, cell culture medium with different con-
centration of T-DNT-30Apt-3, T-DNT-30Apt-6, S-DNT-
30Apt-3 and S-DNT-30Apt-6 (CDNT: 2, 4 and 6 nM) were
added to each well and incubated for 48 h to investigate the
differences of anti-cancer activities of each group.
Bioactivity of Apt was evaluated by incubation of Apt,
T-DNT-15Apt-3, T-DNT-15Apt-6, T-DNT-30Apt-3 and
T-DNT-30Apt-6 with cells at different concentrations (CApt:
15, 30, 60 and 120 nM) for 48 h. Chemotherapy of free DOX,
DOX@T-DNT, and DOX@T-DNT-30Apt-6 was determined
by incubation with cells for 48 h at different concentrations
of DOX (CDOX: 0.5, 1 and 5 µM; CDNT: 4 nM). Bioactivity
and chemotherapy of the developed nanocarriers were stu-
died by treatment cells with DOX, DOX@T-DNT and
DOX@T-DNT-30Apt-6 at different concentrations (CDNT:
2, 4 and 6 nM; CDOX: 1 µM) for 48 h. After each incubation,
CCK8 assay was carried out following the manufacturer’s
instruction. The Uv-vis absorbance (OD) of the medium at
450 nm was measured by a microreader and the inhibition










Cellular uptake of DOX was imaged by confocal laser
scanning microscopy (CLSM, Olympus, Tokyo, Japan)
and quantified by flow cytometric analysis (BD
FACSCanto II, USA). K299 cells were seeded in 12-well
plates for 12 h before each experiment.
For the CLSM imaging, cells were treated with DOX,
DOX@T-DNT and DOX@T-DNT-30Apt-6 (CDNT: 4 nM,
CDOX: 1 μM) for different times. At set time points (0.5, 1,
2 and 4 h), the uptake process was terminated by adding
ice-cold PBS. The excess DOX or DOX-loaded nanocar-
riers were removed by another 3 times washing steps with
PBS. Subsequently, the cells were fixed with 4% parafor-
maldehyde and cell nuclei were stained with DAPI
(10 μg/mL, 15 min), followed by CLSM imaging.
Intracellular location of T-DNT-30Apt-6 was also investi-
gated by CLSM. In brief, K299 cells were incubated with
FAM-T-DNT-30Apt-6 (CDNT: 4 nM). After 4 h, cellular
uptake was stopped by ice-cold PBS. Cells were further
fixed, stained and imaged as the same procedure.
With respect to intracellular DOX quantification, cells
were incubated with DOX, DOX@T-DNT and
DOX@T-DNT-30Apt-6 (CDNT: 4 nM, CDOX: 1 μM) for
4h. The cellular uptake was terminated by ice-cold PBS
and the excess DOX or DOX-loaded carriers were
removed by washing cells with PBS for 3 times. 10,000
cells were automatically collected and intracellular signal
of DOX was quantified by flow cytometric analysis (BD
FACSCanto II, USA).
Cell Apoptosis
Apoptotic cells were determined by dual staining with an
Annexin V-FITC and propidium iodide (PI) kit. Typically,
K299 cells (2×105 cells/well) were seeded in 12-well
plates and incubated at the standard cell culture conditions
for 12 h. The cells were treated with DOX, DOX@T-DNT
and DOX@T-DNT-30Apt-6 (CDNT: 4 nM, CDOX: 1 μM).
After 48 h, cells were collected and washed thrice with
PBS. The cells were resuspended in 1 mL of binding
buffer followed by treatment with FITC-Annexin
V (5 μL, 20 min) and PI (5 μL, 10 min) in turn. The cell
Chen et al Dovepress
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suspension was incubated for 15 min in the dark before
flow cytometric analysis.
Reactive Oxygen Species (ROS)
Reactive oxygen species assay kit was used to analyze
ROS levels in K299 cells. Briefly, K299 cells (2×105
cells/well) were seeded in a 12-well plate. After incubation
for 12 h, cells were treated with DOX, DOX@T-DNT and
DOX@T-DNT-30Apt-6 (CDNT: 4 nM, CDOX: 1 μM) and
further incubated at standard conditions. After 48 h, the
cells were collected and washed with PBS for 3 times. The
cells were resuspended in 500 μL of cell culture medium
containing 2,7-Dichlorofluorescin diacetate (DCFH-DA;
10 μM, 500 μL). All samples were incubated under stan-
dard conditions for another 25 min and washed with cell
culture medium (without FBS) and PBS for several times
before flow cytometric analysis.
Cell Cycle
DNA content quantitation assay kits were used for cell
cycle stages measurement. K299 cells were seeded at
a density of 2×105 cells/well in a 12-well plate. After
incubation for 12 h, cells were treated with the fresh
medium which contained DOX, DOX@T-DNT, and
DOX@T-DNT-30Apt-6 (CDNT: 4 nM, CDOX: 1 μM).
After cultivation for 48 h, cells were collected
(1000 rpm, 5 min) and washed twice with PBS. The pellets
were redispersed in 500 µL of ethanol (70%) and incu-
bated at 4°C overnight for fixation. Cells were washed
with PBS twice to remove any ethanol and treated with
RNase (100 µL) at 37°C for 30 min, and stained with PI
(200 µL, 30 min) for flow cytometric analysis.
Western Blot
K299 cells were seeded in a 6-well plate at a density of
5×105 cells/well. After treatment with DOX,
DOX@T-DNT and DOX@T-DNT-30Apt-6 (CDNT: 4
nM, CDOX: 1 μM) for 48 h, cells were collected and
washed twice with ice-cold PBS, followed by lysis in
RIPA tissue/cell lysis buffer (radio immunoprecipitation
assay; 1 mM, 50 µL; Solarbio Science) for 30 min on an
ice bath. The cells were mixed every 10 min during the
lysis. Samples were collected by centrifugation
(14,000×g, 10 min, 4°C) and quantified by a BCA kit
(Bradford Protein Assays, Thermo Fisher Scientific,
Germany).24 Subsequently, the samples (20 µg) were
separated on a sodium dodecyl sulfate-polyacrylamide
gel (SDS-PAGE; 12%, 120 V, 1 h) and transferred onto
a polyvinylidene fluoride (PVDF) membrane via wet
transfer (200 mA, 1 h). After being blocked with nonfat
milk at room temperature (5%, in PBST (0.1% of Tween
20 in PBS); 3 h, 100 rpm), the membrane was incubated
with primary antibody (1:1000; PBST; overnight, 4°C).
After being washed with PBST (3 times, 30 min), the
membrane was further incubated with the secondary
antibody (1:10,000, PBST; 2 h, 100 rpm). Protein sig-
nals were developed with an enhanced chemilumines-
cence kit (Merck Millipore, Darmstadt, Germany).
Statistical Analysis
All data were expressed as the mean ± SD. The graphs
were performed by Origin 8.0. Statistical analyses were
performed using SPSS. All data were compared with
a single factor analysis of variance (ANONA). The results
of flow cytometric analysis were performed by Flow Jo
software. All experiments in this study were conducted at
least three times.
Results and Discussion
Construction and Characterization of
DNA Nanotubes
The scaffold DNA was extracted from M13mp18, as
shown in Supporting Information Figure S1. Scaffolds
can be folded into S-DNT and T-DNT with the help
of staples (Tables S1 and S2) via DNA origami
nanotechnology.25 Extending the sequence at the end
of staples is a simple method to immobilize Apt on
DNA nanostructures.15 These staples provide possibili-
ties for the modification of Apt at different positions to
achieve the controllable quantity and spatial distribution
of Apt on the DNA nanotubes. In the present study,
scaffolds with 8634 or 7560 bases were folded into
T-DNT and S-DNT by one step annealing
respectively.26 By extending staple with a sequence of
Apt, DNT-Apt with different spatial distribution (3 or 6
nm) and stoichiometry (15 or 30 Apt) were constructed
(Scheme 1, Figure S2) for precise treatment of cancer.
The optimized conditions for the synthesis of DNA
nanotubes are as follows: the concentration of Mg2+ is
5 mM, and the molar ratio of staples to scaffold is 5:1,
as shown in Figure S3.
DNA nanotubes were characterized by TEM and agar-
ose gel electrophoresis. Figure 1A and B showed the
TEM images of T-DNT-30Apt-6 and S-DNT-30Apt-6,
respectively. Both DNA nanotubes are uniform with
Dovepress Chen et al
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Scheme 1 Schematic illustration of Apt (C2NP) anchoring DNA nanotubes (DNT) for biotherapy and chemotherapy. On the one hand, the developed nanocarriers could
effectively get access to cells by CD30 receptor moderated endocytosis which can increase the chemotherapy of doxorubicin (DOX). On the other hand, Apt modified









Figure 1 Characterization of DNA nanostructures. (A) TEM image of T-DNT-30Apt-6. (B) TEM image of S-DNT-30Apt-6. (C) Agarose gel electrophoresis analysis of
scaffold, T-DNT, T-DNT-30Apt-6 and T-DNT-15Apt-6.
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nanorod-like morphology. The size is about 140 nm × 14
nm. Given that the length of Apt is only 31 nt, they are
too small to be imaged by TEM. Migration of scaffold,
T-DNT, T-DNT-30Apt-6, and T-DNT-15Apt-6 in an agar-
ose gel is shown in Figure 1C. The slight retardation
difference among scaffold, T-DNT, T-DNT-30Apt-6 and
T-DNT-15Apt-6 suggested the different molecular
weights of the structures. Slower migrations are observed
in Apt loaded T-DNT.
Drug Loading, Stability and Release
DOX was loaded to T-DNT for chemotherapy of lym-
phoma in vitro by the hydrogen bond between the amino
group of DOX and cytosine of DNA.8 After incubation
T-DNT (4 nM, 20 μL) with DOX (256 μM, 20 μL) in the
dark for 3 h, ~5 molecules of DOX were inserted to each
base pair, which was the maximum loading capacity. The
successful encapsulation of DOX can be proved either by
the zeta potential shift from −25.6 mV to −17.6 mV
(Figure S4) or by the UV-vis absorbance of
DOX@S-DNT-30Apt-6 at 486 nm (Figure S5). The stabi-
lity of T-DNT and DOX were investigated in cell culture
medium with 10% of FBS at 37°C before anti-cancer
studies. As shown in Figure 2A, T-DNT was stable in
cell culture medium at least for 8 h and some T-DNT
had been degraded at 12 h. Compared with free DOX,
the fluorescence of DOX@T-DNT-30Apt-6 was much
higher after incubation in cell culture medium for
48 h (Figure 2B). These results demonstrated that
T-DNT-30Apt-6 could protect DOX from directly
interacting with cell culture medium, resulting in the
improvement of the structural stability of DOX in cell
culture medium.26
Figure 2C showed the release property of DOX from
S-DNT-30Apt-6 and T-DNT-30Apt-6. DOX@S-DNT-
30Apt-6 and free DOX exhibited similar release proper-
ties. However, the release of DOX from T-DNT-30Apt-6
was much slower in 24 h, which may be due to the
more compact structure of T-DNT.26 Given that T-DNT-
30Apt-6 showed a controllable release of DOX, T-DNT
was selected for further study.
In vitro Anticancer Activity
In vitro anti-tumor activity of DOX@T-DNT-Apt and
DOX@S-DNT-Apt were studied on K299 cells with
a standard CCK-8 assay. Given that Apt can activate
CD30 receptors which could induce cell apoptosis17 and
DOX can kill cancer cells, both chemotherapy and biother-
apy were investigated in the present study.
Figure S6 confirms that both origami buffer and
T-DNT were not cytotoxic at the concentrations which
were used for the following studies. Human gastric
epithelial cell line (Ges-1) which has low expression
of CD30 receptors was used as a negative control
experiment. As shown in Figure S7, Apt and Apt mod-
ified DNT showed no significant effects on Ges-1 cell
activities even with a high concentration of Apt
(120 nM).
We firstly investigated biotherapy of S-DNTand T-DNT
to confirm that the spatial distribution of Apt on T-DNT
remains the same as designed in S-DNT. As shown in


























































Figure 2 Time-dependent stability of T-DNT and DOX, and the release study of DOX from DNA nanotubes in Vitro. (A) Agarose gel analysis of T-DNT after incubation
with cell medium plus 10% of FBS for different periods of time. (B) Comparation of the relative stability of free DOX and DOX@T-DNT-30Apt-6 in cell medium plus 10% of
FBS. (C) Release curves of DOX from DOX@T-DNT-30Apt-6 and DOX@S-DNT-30Apt-6 in PBS.
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Figure 3A, at 2 nM of DNT (CApt: 60 or 30 nM), S-DNT-
30Apt-3, T-DNT-30Apt-3, S-DNT-15Apt-6 and T-DNT-
15Apt-6 showed similar cytotoxicity on K299 cells due to
the low concentration of Apt. At 4 nM (CApt: 120 or 60 nM)
and 6 nM (CApt: 180 or 90 nM), cell inhibition rates of
S-DNT-30Apt-6 and T-DNT-30Apt-6 (p>0.05) showed no
significant difference (p>0.05), which is similar between
S-DNT-30Apt-3 and T-DNT-30Apt-3. These results indi-
cate that the spatial distribution of Apt in T-DNT is the same
as S-DNT. Furthermore, T-DNT-30Apt-6 and S-DNT-
30Apt-6 demonstrated significantly higher cell inhibition
rate than T-DNT-30Apt-3 and S-DNT-30Apt-3 (p<0.001).
These results can be explained by the fact that the distance
between the binding site of CD30 on the cell membrane is
about 5.7 nm22 and S-DNT-30Apt-6 and T-DNT-30Apt-6
activated more CD30 receptors which induced more cell
apoptosis.17,22 Besides, T-DNT could control the release of
DOX, and further studies were carried out on T-DNT.
We then optimized the spatial distribution and con-
centration of Apt for biotherapy. Figure 3B shows the
biotherapy of T-DNT with different spatial distribution
and stoichiometry of Apt. Similarly, at the lower con-
centration of Apt (15 nM and 30 nM), there were no















































































Figure 3 In Vitro anti-cancer activity of DNA nanostructures against K299 cells. (A) Bioactivity of S-DNT-30Apt and T-DNT-30Apt with different spatial distributions (3 or 6
nm) (*P<0.001). (B) Optimization of concentration and spatial distribution of Apt on DNA nanostructures (*P<0.001, T-DNT-30Apt-6 vs T-DNT-30Apt-3 and T-DNT-15Apt-
6). (C) Synergetic bioactivity and chemotherapy of DOX, DOX@T-DNT and DOX@T-DNT-30Apt-6 against K299 cells with various concentrations of DOX (*P<0.001,
DOX@T-DNT-30Apt-6 vs Free DOX and DOX@T-DNT). (D) Synergetic bioactivity and chemotherapy of DOX, DOX@T-DNT and DOX@T-DNT-30Apt-6 against K299
cells with various concentrations of DNA nanostructures (*P<0.001, DOX@T-DNT-30Apt-6 vs free DOX and DOX@T-DNT).
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each group. However, with the increase of concentration
of Apt (60 nM and 120 nM), the anti-cancer activity
varies. T-DNT-30Apt-6 exhibited excellent anti-cancer
activities, and the inhibition rate was the highest when
the concentration of Apt was 120 nM. What’s more,
anti-cancer activity of DNA nanotubes with 6 nm
between Apt was superior to that of 3 nm. These results
indicated that a high concentration of Apt with 6 nm of
spatial distribution indeed increased cell apoptosis.
Therefore, a higher concentration of T-DNT-30Apt-6
(CDNT=4 nM, CApt=120 nM) was used for the study of
chemotherapy of DOX.
We further optimized the concentration of DOX to
obtain the maximum chemotherapy of the nanocarriers.
As shown in Figure 3C, at the same level of DOX, the
inhibition rate of DOX@T-DNT was slightly higher
than free DOX, but much lower than DOX@T-DNT-
30Apt-6. DOX@T-DNT-30Apt-6 exhibited the highest
inhibition rate at 0.5 µM and 1 µM of DOX. These
results revealed that T-DNT increased the anti-cancer
activity of DOX and Apt promoted DNA nanocarriers
to get access to tumor cells. However, 5 µM of DOX
was so high that the anti-cancer activity in free DOX,
DOX@T-DNT, and DOX@T-DNT-30Apt-6 all showed
high cell inhibition rates. Hence, 1 µM of DOX was
used for the study of the combination of chemotherapy
and biotherapy.
Figure 3D shows the combination of chemotherapy and
biotherapy of DOX@T-DNT-30Apt-6. Compared to free
DOX and DOX@T-DNT, DOX@T-DNT-30Apt-6 exhib-
ited a higher anti-cancer activity at different concentra-
tions. The anti-cancer activity of DOX@T-DNT-30Apt-6
increased along with the increase of concentration. The
inhibition rate of DOX@T-DNT-30Apt-6 (CDNT=4 nM,
CDOX=1 µM) was much higher than that of either Apt
(Figure 3B) or free DOX at the same conditions. These
findings revealed that DOX@T-DNT-30Apt-6 exhibited
both chemotherapy and biotherapy. Chemotherapy of
DOX and biotherapy of Apt could be further enhanced
after combination.
Cellular Uptake
Cellular uptake of DOX, DOX@T-DNT, and
DOX@T-DNT-30Apt-6 was also studied. As shown in
Figure 4A and Figure S8, cells which were treated with
DOX@T-DNT-30Apt-6 showed the strongest fluores-
cence signal of DOX. Quantitative analysis of intracel-
lular DOX by flow cytometry (Figure 4B) further
revealed that cells treated with DOX@T-DNT-30Apt-6
showed the highest (99.9%) DOX level. These results
demonstrate that Apt improved the cellular uptake of
DOX by CD30 receptor moderated endocytosis.27
Thereby, chemotherapy of DOX can be significantly
enhanced.
Intracellular location of FAM-T-DNT-30Apt-6 was
investigated by CLSM (Figure 4C). After incubation
with K299 cells for 4 h, FAM-T-DNT-30Apt-6 was
mainly accumulated around the cell nucleus and no
signal of FAM was detected inside the cell nucleus.
This experiment demonstrated that FAM-T-DNT-30Apt-
6 can be taken up by cells and cannot be digested into
small fractions which can get access to the cell nucleus
within 4 h.
Mechanism of Cell Inhibition
The anti-cancer activity of DOX is achieved by insert-
ing DNA base pairs and inhibiting topoisomerase II.8
Previous studies have shown that DOX affects cell
apoptosis, cell cycle, and intracellular ROS levels.19
As shown in Figure 5A, free DOX increased early-
stage cell apoptosis from 7.2% to 37.4%. After being
loaded to T-DNT, cell apoptosis was slightly increased
to 41.1%. Due to Apt, cell apoptosis was further
increased to 62.3% by DOX@T-DNT-30Apt-6.
A similar phenomenon was observed in the ROS ana-
lysis (Figure 5B). Intracellular ROS levels were
increased sharply in DOX@T-DNT-30Apt-6 (58.7%).
Figure 5C confirms that free DOX mainly arrested
cell cycle at S stage. And the percentage of cells
which were arrested at G2/M was slightly increased
to 26.66%. Compared to free DOX, DOX@T-DNT
mainly arrested less on G2/M. With the help of Apt,
cell cycle arrest in G2/M was further increased to
33.99% in DOX@T-DNT-30Apt-6 group. This result
matches our previous study that Apt can slightly arrest
cells in G2/M.19
It was reported that Apt could bind to CD30 receptors and
upregulated the downstream signaling, resulting in cell
apoptosis.28 Our previous study showed that Apt could result
in cell apoptosis, arrest cell cycles in G2/M, and upregulated
the intracellular ROS level.19 However, it is still unclear
whether Apt has effects on some cell signaling. It is well
known that tumor suppressor gene p53 plays a crucial role in
cell cycle and cell proliferation.24 We therefore investigated
whether DOX@T-DNT-30Apt-6 could induce p53 mediated
apoptosis in K299 cells. Western blot analysis showed that
Dovepress Chen et al
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both free DOX andDOX@T-DNTcould promote the expres-
sion of p53 protein (Figure 5D). Moreover, the expression
level of p53 was further increased in DOX@T-DNT-30Apt-6
group. These results demonstrated that Apt might induce the
apoptosis of K299 cells by inducing the increase of p53
protein expression.
Conclusions
To summarize, we have synthesized tumor-targeting T-DNT
nanocarriers by immobilization of Apt with different spatial
distribution and stoichiometry. The spatial distribution of Apt
which matched the distance of binding sites of CD30 receptors
exhibited stronger anti-cancer activity. Furthermore, we investi-
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Figure 4 Intracellular uptake of DOX, DOX@T-DNT and DOX@T-DNT-30Apt-6. (A) CLSM images of K299 cells after incubation with DOX, DOX@T-DNT and
DOX@T-DNT-30Apt-6 for 4h. (B) Flow cytometry histogram profiles of intracellular uptake of DOX after incubation with DOX, DOX@T-DNTand DOX@T-DNT-30Apt-
6 for 4 h. (C) CLSM images of K299 cells after incubation with FAM-T-DNT-30Apt-6 for 4 h.
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gated the anti-tumormechanism ofApt. Our results showed that
the interaction between C2NP and its receptor CD30 could
upregulate the expression of p53, resulting in K299 cells apop-
tosis. Our work demonstrated that Apt modified T-DNT is not
only a promising strategy for targeting delivery but also an
efficient solution for the synergistic treatment of cancer.
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Figure 5 Mechanism study of the anti-cancer activity of DOX@T-DNT and DOX@T-DNT-30Apt-6. Representative results of the impacts of free DOX and different DNA
origami carriers on (A) cell apoptosis, (B) ROS content (C) cell cycle and (D) p53 expression.
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